Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
To evaluate the tolerability and safety of ONO-7475 monotherapy and combinations with ONO-4538 in patients with advanced or metastatic solid tumors
Advanced or Metastatic Solid Tumors
DRUG: ONO-7475|DRUG: ONO-7475 + ONO-4538
Number of paticipants with dose-limiting toxicities during the DLT evaluation period, 28 days|Incidence and severity of adverse events as assessed by CTCAE v4.0 to determine the tolerability and safety, Through study completion, an average of 1 year
Pharmacokinetics (Cmax), Assessment of the maximum plasma concentration of ONO-7475 both alone and in combination with ONO-4538, Through study completion|Pharmacokinetics (Tmax), Assessment of the time to reach maximum observed plasma concentration of ONO-7475 both alone and in combination with ONO-4538, Through study completion|Pharmacokinetics (AUC), Assessment of the plasma area under the curve of ONO-7475 both alone and in combination with ONO-4538, Through study completion
To evaluate the tolerability and safety of ONO-7475 monotherapy and combinations with ONO-4538 in patients with advanced or metastatic solid tumors